阿立哌唑联合丙戊酸钠治疗躁狂症的临床分析

Clinical analysis of aripiprazole with sodium volproate in the treatment of patients with manic symptom

目的：探讨阿立哌唑联合丙戊酸钠治疗躁狂症的临床疗效和安全性。方法：将97例符合CCMD-3诊断心境障碍躁狂相的患者随机分为观察组51例，对照组46例，观察组采用阿立哌唑联合丙戊酸钠治疗，对照组采用氯丙嗪联合丙戊酸钠治疗，疗程均为6周。疗程结束后采用躁狂量表及副作用量表评定临床疗效和不良反应。结果：治疗6周末观察组有效率98．04％（50／51），对照组为78．26％（36／46）；观察组TESS量表评分较对照组低，两组疗效比较差异有非常显著性（P〈0．01）。结论：阿立哌唑联合丙戊酸钠治疗躁狂症疗效显著、安全性高、依从性好，值得临床推广应用。

Objective：To explore curative effects and safety of aripiprazole with sodium volproate in the treatment of patients with manic symptom. Methods：97 patients who met CCMD-3 criteria for mania were divided randomly into the intervention group（51 cases） and the control group（46 cases） ,the intervention group were treated with aripiprazole with sodium volproate for 6 weeks,the control group were treated with chlorpromazine with sodium volproate for 6 weeks, curative effectiveness were assessed with BechRafaelsen Mania Rating Scale（BRMS） and side effects with the Treatment Emergent Symptom Scale（TESS）. Results：After 6 week treatment,effectiveness rates was 98. 04% in the intervention group, and 78.26% in the control group, the side effects of intervention group were lighter than control group, there were significant difference in the curative effects were compared between two groups（P〈0. 01）. Conclusions：aripiprazole with sodium volproate in the treatment of patients with manic symptom has evident effective , higher safety and better compliance,and hence is worthy of being recommended in clinical practice.